RxDoctor Payments Data

Douglas Triffon, MD

Cardiovascular Disease · la Jolla, CANPI 1952358632

Payments from drug & device makers

$175,617in general payments, 2019–2025

Across 631 payments — averaging $278.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$88K
  • Esperion Therapeutics, Inc.$36K
  • Amgen$19K
  • Sanofi-aventis U.S. LLC$16K
  • Regeneron Healthcare Solutions, Inc.$9K
  • Novartis$4K
  • plus $3K from 29 others

What the payments were for

  • Consulting fees$2,5321%
  • Speaking & faculty fees$146,00383%
  • Travel & lodging$14,6198%
  • Food & beverage$12,4467%
  • Education$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$175,617 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$449,041
Medicare patients
2,913
Services billed
6,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab477$585,879
EliquisApixaban221$321,031
Praluent PenAlirocumab189$244,723
EntrestoSacubitril/Valsartan100$128,848
JardianceEmpagliflozin94$123,099
NexletolBempedoic Acid74$69,841
XareltoRivaroxaban35$51,786
VascepaIcosapent Ethyl56$46,694
BrilintaTicagrelor34$35,763
Ezetimibe1,034$32,164
FarxigaDapagliflozin Propanediol23$27,014
ZetiaEzetimibe30$19,879
Colesevelam Hcl35$18,324
Icosapent Ethyl49$16,997
Eplerenone139$14,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$243$321,031221 claims
NovartisEntresto$4,198$128,848100 claims
Boehringer IngelheimJardiance$450$123,09994 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$35,515$80,23386 claims
AstraZenecaBrilinta, Farxiga, Crestor$313$74,39068 claims
Johnson & JohnsonXarelto$105$51,78635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →